Search

Your search keyword '"Li, Lingna"' showing total 396 results
Start Over Author "Li, Lingna"
396 results on '"Li, Lingna"'

8. Supplementary Figure S2 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Author

Fan, Huishou, primary, Wang, Bing, primary, Shi, Lihui, primary, Pan, Ni, primary, Yan, Wenqiang, primary, Xu, Jingyu, primary, Gong, Lixin, primary, Li, Lingna, primary, Liu, Yuntong, primary, Du, Chenxing, primary, Cui, Jian, primary, Zhu, Guoqing, primary, Deng, Shuhui, primary, Sui, Weiwei, primary, Xu, Yan, primary, Yi, Shuhua, primary, Hao, Mu, primary, Zou, Dehui, primary, Chen, Xiequn, primary, Qiu, Lugui, primary, and An, Gang, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Methods S1 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Author

Fan, Huishou, primary, Wang, Bing, primary, Shi, Lihui, primary, Pan, Ni, primary, Yan, Wenqiang, primary, Xu, Jingyu, primary, Gong, Lixin, primary, Li, Lingna, primary, Liu, Yuntong, primary, Du, Chenxing, primary, Cui, Jian, primary, Zhu, Guoqing, primary, Deng, Shuhui, primary, Sui, Weiwei, primary, Xu, Yan, primary, Yi, Shuhua, primary, Hao, Mu, primary, Zou, Dehui, primary, Chen, Xiequn, primary, Qiu, Lugui, primary, and An, Gang, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S3 from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Author

Fan, Huishou, primary, Wang, Bing, primary, Shi, Lihui, primary, Pan, Ni, primary, Yan, Wenqiang, primary, Xu, Jingyu, primary, Gong, Lixin, primary, Li, Lingna, primary, Liu, Yuntong, primary, Du, Chenxing, primary, Cui, Jian, primary, Zhu, Guoqing, primary, Deng, Shuhui, primary, Sui, Weiwei, primary, Xu, Yan, primary, Yi, Shuhua, primary, Hao, Mu, primary, Zou, Dehui, primary, Chen, Xiequn, primary, Qiu, Lugui, primary, and An, Gang, primary

Published
2024
Full Text
View/download PDF

11. Data from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Author

Fan, Huishou, primary, Wang, Bing, primary, Shi, Lihui, primary, Pan, Ni, primary, Yan, Wenqiang, primary, Xu, Jingyu, primary, Gong, Lixin, primary, Li, Lingna, primary, Liu, Yuntong, primary, Du, Chenxing, primary, Cui, Jian, primary, Zhu, Guoqing, primary, Deng, Shuhui, primary, Sui, Weiwei, primary, Xu, Yan, primary, Yi, Shuhua, primary, Hao, Mu, primary, Zou, Dehui, primary, Chen, Xiequn, primary, Qiu, Lugui, primary, and An, Gang, primary

Published
2024
Full Text
View/download PDF

13. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)

Author

Fan, Huishou, primary, Wang, Bing, additional, Shi, Lihui, additional, Pan, Ni, additional, Yan, Wenqiang, additional, Xu, Jingyu, additional, Gong, Lixin, additional, Li, Lingna, additional, Liu, Yuntong, additional, Du, Chenxing, additional, Cui, Jian, additional, Zhu, Guoqing, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Xu, Yan, additional, Yi, Shuhua, additional, Hao, Mu, additional, Zou, Dehui, additional, Chen, Xiequn, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2024
Full Text
View/download PDF

14. Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET

Author

Lim, Reyna KV, primary, Buschman, Matthew, additional, Khasanov, Alisher, additional, Ledesma, Arthur, additional, Chen, John, additional, Nguyen, Thanhtruc, additional, Guo, Joanna, additional, Li, Lingna, additional, Huang, Jonathan, additional, Niu, Jin, additional, Kerwin, Lisa, additional, Wang, Rengang, additional, Guo, Yurong, additional, Zhu, Tong, additional, Kaufmann, Gunnar, additional, Zhang, Yanliang, additional, Zhou, Heyou, additional, Ji, Henry, additional, and Fu, Yanwen, additional

Published
2023
Full Text
View/download PDF

16. Early relapse within 18 months (ER18) is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma

Author

Yan, Wenqiang, primary, Xu, Jingyu, additional, Fan, Huishou, additional, Li, Lingna, additional, Cui, Jian, additional, Du, Chenxing, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Xu, Yan, additional, Hao, Mu, additional, Anderson, Kenneth C., additional, Zou, Dehui, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2023
Full Text
View/download PDF

17. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma

Author

Du, Chenxing, primary, Li, Lingna, additional, Fan, Huishou, additional, Mao, Xuehan, additional, Liu, Jiahui, additional, Xu, Yan, additional, Sui, Weiwei, additional, Deng, Shuhui, additional, Li, Chengwen, additional, Zhao, Jiawei, additional, Yi, Shuhua, additional, Hao, Mu, additional, Zou, Dehui, additional, Zhao, Yaozhong, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2023
Full Text
View/download PDF

18. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, additional, Fan, Huishou, additional, Xu, Jingyu, additional, Li, Lingna, additional, Du, Chenxing, additional, Mao, Xuehan, additional, Yan, Yuting, additional, Xu, Yan, additional, Sui, Weiwei, additional, Deng, Shuhui, additional, Yi, Shuhua, additional, Anderson, Kenneth C., additional, Qiu, Lugui, additional, Zou, Dehui, additional, and An, Gang, additional

Published
2023
Full Text
View/download PDF

19. FIGURE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

20. TABLE 1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

21. Table S2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

22. TABLE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

23. Figure S1 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

24. FIGURE 4 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

25. FIGURE 2 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

26. FIGURE 3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

27. Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

28. Optimization of Single Train Operations

Author

Li, Lingna, Wang, Xinxin, Liu, Yuxin, Chen, Chao, Kacprzyk, Janusz, Series editor, Pal, Nikhil R., Advisory editor, Bello Perez, Rafael, Advisory editor, Corchado, Emilio, Advisory editor, Hagras, Hani, Advisory editor, Kóczy, László T., Advisory editor, Kreinovich, Vladik, Advisory editor, Lin, Chin-Teng, Advisory editor, Lu, Jie, Advisory editor, Melin, Patricia, Advisory editor, Nedjah, Nadia, Advisory editor, Nguyen, Ngoc Thanh, Advisory editor, Wang, Jun, Advisory editor, Balas, Valentina Emilia, editor, Jain, Lakhmi C., editor, and Zhao, Xiangmo, editor

Published
2017
Full Text
View/download PDF

33. Figure S2 from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

34. Table S3 from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

35. Data from Clinical benefit of autologous stem cell transplantation for multiple myeloma patients achieving undetectable minimal residual disease after induction treatment

Author

Liu, Jiahui, primary, Yan, Wenqiang, primary, Fan, Huishou, primary, Xu, Jingyu, primary, Li, Lingna, primary, Du, Chenxing, primary, Mao, Xuehan, primary, Yan, Yuting, primary, Xu, Yan, primary, Sui, Weiwei, primary, Deng, Shuhui, primary, Yi, Shuhua, primary, Anderson, Kenneth C., primary, Qiu, Lugui, primary, Zou, Dehui, primary, and An, Gang, primary

Published
2023
Full Text
View/download PDF

36. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

Author

Cui, Jian, primary, Lv, Rui, additional, Yu, Tengteng, additional, Yan, Wenqiang, additional, Xu, Jingyu, additional, Fan, Huishou, additional, Li, Lingna, additional, Liu, Yuntong, additional, Du, Chenxing, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Xu, Yan, additional, Yi, Shuhua, additional, Zou, Dehui, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2023
Full Text
View/download PDF

37. Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma

Author

Yan, Wenqiang, primary, Fan, Huishou, additional, Xu, Jingyu, additional, Liu, Jiahui, additional, Li, Lingna, additional, Du, Chenxing, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Xu, Yan, additional, Zou, Dehui, additional, Qiu, Lugui, additional, and An, Gang, additional

Published
2023
Full Text
View/download PDF

42. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.

Author

Yan, Wenqiang, Xu, Jingyu, Fan, Huishou, Li, Lingna, Cui, Jian, Du, Chenxing, Deng, Shuhui, Sui, Weiwei, Xu, Yan, Hao, Mu, Anderson, Kenneth C., Zou, Dehui, Qiu, Lugui, and An, Gang

Abstract

Background: The duration of response to treatment is a major prognostic factor, and early relapse (ER) strongly predicts inferior survival in multiple myeloma (MM). However, the definitions of ER in MM vary from study to study and how to dynamically integrate risk distribution is still unsolved. Methods: This study evaluated these ER definitions and further investigated the underlying relationship with static risk distribution in 629 newly diagnosed MM (NDMM) patients from the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199). Results: These data indicated that early relapse within 18 months (ER18) after initial treatment was the best time point for identifying early progression and dynamic high‐risk in MM. The ER18 population (114 of 587, 19.4%) presented with more aggressive biologic features and the inferior response to treatment compared to a reference cohort (p <.001), with a significantly short median overall survival (OS) of 28.9 months. Multivariate analyses confirmed the most significant prognostic value of ER18 on OS in the context of International Staging System stage, elevated lactate dehydrogenase, thrombocytopenia, cytogenetic abnormalities, and treatment (hazard ratio, 4.467; p <.001). The authors also described the specific transitions from static risk profile to dynamic risk distribution and then constructed a mixed‐risk‐pattern to identify four novel populations with distinct survival (p <.001). Additionally, the authors proposed a second‐state model that predicts dynamic risk changes, enabling a complementary role to the Revised International Staging System model in facilitating individualized systematic treatment. Conclusions: Collectively, this study concludes that ER18 is a simple and dynamic prognostic predictor in MM. In addition to static risk assessment, dynamic risk plays an important role in survival prediction. The present study sheds light on the optimal time point for early relapse (ER), defined as relapse within 18 months after initial treatment, and highlights its significant dynamic predictive impact on the prognosis in multiple myeloma. Alongside the conventional static risk stratification at diagnosis, a second‐state model that incorporates ER reveals dynamic risk changes that facilitate individualized systematic treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma.

Author

Fan, Huihsou, Yan, Wenqiang, Li, Lingna, Xu, Jingyu, Liu, Jiahui, Xu, Yan, Sui, Weiwei, Deng, Shuhui, Du, Chenxing, Yi, Shuhua, Zou, Dehui, Qiu, Lugui, and An, Gang

Subjects
MULTIPLE myeloma, DISEASE progression, MONOCLONAL gammopathies, SURVIVAL rate, MULTIVARIATE analysis
Abstract

There may be a shift in risk stratification at progression compared to that at diagnosis in patients with multiple myeloma (MM). We aimed to evaluate whether re-staging and stage migration is of prognostic impact. Real-world data from the National Longitudinal Cohort of Hematologic Diseases-multiple myeloma were collected; 263 consecutive patients demonstrating disease progression were finally included. Staging at diagnosis and re-staging at progression were performed using the International Staging System (ISS) and Revised International Staging System (RISS). Based on ISS re-staging, the median post-progression survival (mPPS) of patients with stage I, II, and III was 44.2, 21.7, and 11.6 months, respectively (P < 0.0001). Based on RISS re-staging, the mPPS of patients with stage I, II, and III was 50.3, 22.2, and 11.4 months, respectively (P < 0.0001). The mPPS in patients with improved, maintained, and deteriorated ISS stage migration from diagnosis was 33.6, 20.9, and 16 months, respectively (P = 0.0051) and that with improved, maintained, and deteriorated RISS stage migration was 48.4, 23.1, and 13.9 months, respectively (P < 0.001). Compared to patients with maintained or improved disease stage, those with deteriorated ISS/RISS migration showed significantly higher incidence of Del(17P) at progression and worse PPS. Multivariate analyses indicated both re-staging and stage migration by ISS/RISS at progression were independent predictors for PPS. We demonstrated that ISS/RISS re-staging showed superior prognostic utility over ISS/RISS staging in predicting PPS. Patients with deteriorated stage migration or maintained advanced stage at progression may need more individualized treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Governing Step of Metastasis Visualized in vitro

Author

Chishima, Takashi, Yang, Meng, Miyagi, Yohei, Li, Lingna, Tan, Yuying, Baranov, Eugene, Shimada, Hiroshi, Moossa, A. Rahim, Penman, Sheldon, and Hoffman, Robert M.

Published
1997

47. Supplementary Data from Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth

Author

Huang, Hanhua, primary, Lai, Jing-Yu, primary, Do, Janet, primary, Liu, Dingguo, primary, Li, Lingna, primary, Del Rosario, Joselyn, primary, Doppalapudi, Venkata R., primary, Pirie-Shepherd, Steven, primary, Levin, Nancy, primary, Bradshaw, Curt, primary, Woodnutt, Gary, primary, Lappe, Rodney, primary, and Bhat, Abhijit, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results